Developing treatments for enteroviruses affecting children
Official title: THERAPEUTICS FOR EMERGING HUMAN ENTEROVIRUSES
Funded at Hdt Bio Corporation · NIH-10684970 · Data updated 2026-11-12
This study is working on developing special antibodies to help fight off enteroviruses like EV-D68, which can make young children very sick, and aims to create new treatments since there aren’t any available right now.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hdt Bio Corporation NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2025 |
| Funding year | 2022 |
| Award (this year) | $1,499,422 |
| NIH project number | 75N93022C00017-0-9999-1 |
| Project ID | NIH-10684970 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who are at risk of or suffering from enterovirus infections.
✕Less likely to help
Patients who are older than 21 years or those not affected by enterovirus infections may not benefit from this research.
What this research studies
This research focuses on creating monoclonal antibodies to combat enteroviruses, particularly EV-D68, which can cause severe respiratory and neurological issues in young children. The project aims to develop effective therapeutics since there are currently no available treatments or vaccines for this virus. By targeting the enterovirus family, the research seeks to provide a broad-spectrum solution that could help protect vulnerable pediatric populations from serious health complications. The approach involves advanced antibody development techniques to ensure efficacy against these pathogens.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for enterovirus infections, significantly improving health outcomes for affected children.
How similar studies have gone: Other research has shown promise in developing monoclonal antibodies for viral infections, indicating potential success for this approach.
Where this research is happening
-
Hdt Bio Corporation
Seattle, United States Active
Researchers
- Principal investigator: Sar, Kandyma — Hdt Bio Corporation
- Study coordinator: Sar, Kandyma
Related research
Other NIH-funded projects on the same topics.
-
How muscle-targeted self-replicating RNA vaccines trigger immunity
This project looks at how self-amplifying RNA vaccines delivered to muscle activate immune responses to protect people from respiratory viruses like COVID-19, RSV, and influenza.
-
Developing an RNA vaccine to enhance the immune response against HIV
This study is testing a new mRNA vaccine that aims to help your immune system fight HIV-1 by encouraging it to produce strong antibodies, using a special delivery method to make it work better.
-
Innovative RNA vaccines for tuberculosis targeting the mucosal immune system
This study is working on a new RNA vaccine to help boost the immune system's fight against tuberculosis, especially in the lungs, and it's designed to be both effective and affordable for people who need it.
-
How muscle-targeting RNA vaccines work against viruses
This study is testing a new kind of RNA vaccine designed to help your body fight off viral infections like COVID-19 by boosting your immune response, and it’s looking for participants to see how well it works and if it’s safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.